Viswa Colluru (@viswacolluru) header
Viswa Colluru (@viswacolluru) profile picture

Founder & CEO @enveda I Son, husband, and teammate I India ‣ US for PhD @UWMadison I Love solving hard problems with amazing people

Joined July 2019
Photo by Viswa Colluru (@viswacolluru)
Another one to round out a big year at Enveda! 130 million more chances to deliver new hope to patients, the work experience of a lifetime for our employees, incredible returns to our investors, breakthrough technology to the world, and knowledge (Veda) to humanity 🚀
We’re thrilled to announce $130M in Series C funding led by @KinnevikAB and FPV, with participation from @BaillieGifford , @premjiinvest , @Lux_Capital , @trueventures , and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials. In just 4 short years since our seed round, we’ve gone from a concept to a clinical-stage company with a deep pipeline of 10 development candidates. 🚀 Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates 4x faster than industry average—a testament to our thesis, technology, and team. This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible. Here’s to the next chapter of growth, discovery, and development! 💊💡 Learn more here: tinyurl.com/545v3bwu Read our feature in @Bloomberg here: tinyurl.com/yj4e8j8f
8
5
1
53
9,343
Viswa Colluru retweeted
Chemistry needs its Alpha Fold moment. We’ve had the data and the algorithms, we now have the benchmarks and the out-of-train test sets thanks to tireless work by @davidwhealey @augustallen and the ML team @enveda. Join the >3000 teams in trying to crack the problem!
Join the @enveda-hosted CASMI! 🌿🚀
2
3
1
27
3,787
Chemistry needs its Alpha Fold moment. We’ve had the data and the algorithms, we now have the benchmarks and the out-of-train test sets thanks to tireless work by @davidwhealey @augustallen and the ML team @enveda. Join the >3000 teams in trying to crack the problem!
Join the @enveda-hosted CASMI! 🌿🚀
2
3
1
27
3,787
Today we can finally talk about @enveda's partnership with @AnthropicAI . “Partnership” is a word that covers a lot of sins, so here is what it actually bought us: 1. a Phase 2 program pulled forward by three weeks 2. an IND submission accelerated for another soon-to-be-announced clinical program 3. an Investigator’s Brochure, drafted by @claudeai and signed off by our team after one minor edit, now in front of the FDA We chose to work with Anthropic on development, not discovery. Enveda already finds medicines faster than we can develop them, and I think the industry is heading the same way. The slowest part of development is paperwork, directly or indirectly: batch records, study reports, the Investigator’s Brochure, and the IND that packages it all for the FDA. Discovery gets the headlines. Document review is where the months go. Test 1: manufacturing batch release for a Phase 2 program. Before a batch can go to a trial, someone checks every page of its manufacturing record by hand. Claude read 1,061 scanned, largely handwritten pages from the campaign. Four of our reviewers and outside consultants independently reviewed the same pages, and a Quality adjudicator scored every comment against one question: would an FDA auditor raise it? Claude matched all 11 actionable issues the experts found and added 7 they had missed. Review time fell from 26 hours (typically spread over several weeks) to under 3, an 89% reduction, for about $37 in model cost. On another program, it flagged a climbing impurity that routine review had cleared; it later went out of specification. Test 2: the Investigator’s Brochure for an IND, drafted in four hours instead of weeks. For a new Enveda medicine about to enter human trials, Claude drafted the brochure every trial physician relies on, from a structured layer of facts pulled from our tox, bioanalytical, and PK reports. Our reviewers found one minor unit-conversion error. We fixed it and included that draft in the IND. From the same source layer, Claude drafted the core of the IND itself in four hours, work that takes the best teams a month or more. None of this works unless the model stays factful, so we built a custom harness to force it. It reads every page as an image, keeps a code ledger of which pages it read, and ties every finding to its page and governing document. Across the evaluation, no finding cited anything that was not in the record. The full method is public. Our technical report on the CMC Document Processor covers the architecture, GMP controls, study design, and results, and we open-sourced a companion implementation so you can build your own! Thank you to the incredible @enveda and @AnthropicAI teams for making this possible.
Patients cannot wait another day for tomorrow’s medicines. Today, bringing a drug to market can take more than 10 years and cost over $1 billion. A major contributor is the time and expense required to generate and review the documentation that helps to build medicines that are safe and effective. That is why we are thrilled to partner with @AnthropicAI to transform drug development, starting with our clinical-stage programs. Together, we built tools to address two major early-stage bottlenecks: preparing a complete IND package and reviewing CMC batch records for release. The results have been groundbreaking in speed, cost, and quality. Read more: anthropic.com/research/early…
9
15
4
114
9,945
Surreal!
Enveda on the @Nasdaq Tower in @TimesSquareNYC. This special moment was made even better by having our Founder and CEO, @viswacolluru there in person to take it in. The display marked our $311 million Series E and the years of work behind it: every experiment, every molecule, every late night, every setback that taught us something, and every hard problem solved by our team. The financing reflects the confidence an exceptional group of investors has placed in Enveda’s platform, pipeline, and long-term ambition. That confidence also carries a responsibility to put the capital to work with discipline and urgency, moving our medicines forward and continuing to turn life’s chemistry into better options for patients. Thank you to our friends at Nasdaq for marking the moment so beautifull y. #Enveda #LearningfromLife #AI #Biotech
8
49
3,333
Viswa Colluru retweeted
Enveda on the @Nasdaq Tower in @TimesSquareNYC. This special moment was made even better by having our Founder and CEO, @viswacolluru there in person to take it in. The display marked our $311 million Series E and the years of work behind it: every experiment, every molecule, every late night, every setback that taught us something, and every hard problem solved by our team. The financing reflects the confidence an exceptional group of investors has placed in Enveda’s platform, pipeline, and long-term ambition. That confidence also carries a responsibility to put the capital to work with discipline and urgency, moving our medicines forward and continuing to turn life’s chemistry into better options for patients. Thank you to our friends at Nasdaq for marking the moment so beautifull y. #Enveda #LearningfromLife #AI #Biotech
10
1
28
4,346
Viswa Colluru retweeted
Happy Friday. On today's show: - @johnarnold (Arnold Ventures) - @viswacolluru (Enveda) - @jakeadler (Pilgrim Labs) - @adamkorsunsky (FreeBean) See you on the stream.
4
8
3
45
38,513
Viswa Colluru retweeted
Enveda on the New York Stock Exchange cubes today! Grateful to our friends at the @NYSE, Eric Dimise and Johanna Grossman, for putting our $311M Series E up in lights in the financial heart of New York City. This raise opens the next chapter for Enveda as we advance our clinical-stage pipeline and keep turning nature's chemistry into medicines for millions of patients. Onward. #Enveda #LearningfromLife #AI #Biotech
1
5
24
2,370
I started @enveda so mothers could fight their diagnoses with power mine never had. Sept 18 is her birthday. It’s also the day our first IND cleared, our first patient data came in, and now our Series E closed. More backup for the fight ahead. Happy Birthday, Mom!
Today we are announcing a $311M Series E to bring pharma into the 21st century. Enveda started with a thesis: a molecule that evolution has already refined is a better place to begin than one designed from scratch. This year, two first-in-class molecules discovered by Enveda (ENV-294 and ENV-308) had positive readouts in humans. Many more are behind them. We are grateful to @CatalioCapital for leading this round, to our new investors Durable Capital Partners, @ICONIQCapital, @lightspeedvp, Surveyor Capital (a Citadel company), accounts advised by @TRowePrice, @digitalisvc and Alderline Group, and to @BaillieGifford, @PremjiInvest, @trueventures, @KinnevikAB, @FPVventures, @_DimensionCap, @lifeforcecap and @Lux_Capital for continuing to back us. The best is yet to come… Read more: businesswire.com/news/home/2… #Biotech #AI #LearningfromLife
18
13
2
146
9,854
Viswa Colluru retweeted
Atopic Dermatitis needs new and better treatments. See what's around the corner. Link in the comments section. #AtopicDermatitis #Dermatology #DrugDiscovery #Biotech
1
2
1
7
667
Viswa Colluru retweeted
This week in New York, positive Phase 1b data for #ENV294 our potential first-in-class oral therapy for moderate-to-severe #AtopicDermatitis, were presented at the 𝟮𝟬𝟮𝟲 American Academy of Dermatology 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗔𝗰𝗮𝗱𝗲𝗺𝘆. The numbers speak for themselves: • 68% mean reduction in EASI by Day 28, deepening to 85% by Day 42 (exploratory endpoint) • 100% of patients hit EASI-50 — with 78% reaching EASI-75 and 56% reaching EASI-90 (exploratory endpoint) • 44% achieved clear or almost-clear skin (vIGA-AD 0/1), including two patients completely clear (exploratory endpoint) • A generally well-tolerated safety profile (primary endpoint) ENV-294 isn't a new spin on an old pathway. It's a molecular glue designed to stabilize a previously undrugged target, with a mechanism unlike anything currently available in AD. Fighting to address the massive unmet need. This is what happens when you learn from #LifesChemistry, and the real impact of #AI on #Pharma. Next stop: an oral presentation at the 𝗘𝗔𝗗𝗩 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟲 in Vienna this October. See you there! #ClinicalTrials #Dermatology #DrugDiscovery #Biotech businesswire.com/news/home/2…
4
8
446
Viswa Colluru retweeted
The promise of AI to discover medicines that will fundamentally change how we live is happening NOW. Enveda is using AI to analyze biology and chemistry at an unprecedented resolution, unlocking new possibilities for drug discovery that have the potential to transform health and humanity. Don't miss Enveda's Chief Execution Officer, @danwee08, speaking at the inaugural LEAP East conference in Hong Kong next week. July 9 | 10:10 - 10:40 AM The Next Frontier for Therapeutics: AI Driven Innovation | Orbital Stage | LEAP East leapeast.com/events/2026-age… #DrugDiscovery #AI #Biotech
3
6
466
Viswa Colluru retweeted
The potential of #AI in #DrugDiscovery has been discussed for a while, with little to show for it in the clinic. Enveda is changing that. Positive clinical readout, multiple mega-blockbuster clinical pipeline, and a platform that is expanding our understanding of biology through chemistry. Our Founder & CEO, @viswacolluru, will present at the @UBS Private Biotech Innovation Summit on May 18, one of the most selective investor forums for private biopharma companies. Clinical proof that our AI-native platform can produce differentiated medicines at scale, not just interesting molecules. See you there!
4
16
608
Viswa Colluru retweeted
.@viswacolluru thinks most ideas that change the trajectory of human life are actually old. The locomotive was first a steam engine. Electric cars, neural networks, and rockets all existed long before the world caught up to them. The question is not what to invent but which abandoned idea the world is finally ready to revisit, where the ancillary technologies have matured enough to clear the original constraints. For Viswa, that idea is using plant compounds as the starting point for drug discovery. The pharma industry set it aside, and he is revisiting it.
For decades, drug discovery has shifted away from nature and toward biology-first approaches. @viswacolluru believes that shift was a catastrophic mistake. His company, Enveda (@enveda), has raised over $500 million to build a “search engine for nature’s chemistry.” In our conversation, we explore: • Why the pharmaceutical industry abandoned nature (and why that was a massive mistake) • How Enveda built a system to decode unknown molecules in nature • The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work • Why old ideas, from immunotherapy to natural products, often hold the most latent potential • How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million • Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis • Why first-in-class medicines capture the vast majority of returns in pharma • What competitive table tennis taught him about building companies Thank you to the partners who make this possible @brexHQ: The intelligent finance platform: brex.com/mario @ahrefs Brand Radar: Find your brand in AI results: ahrefs.com/generalist @withpersona: Trusted identity verification for any use case: withpersona.com/generalist (00:00) Introduction to Viswa Colluru (07:06) Early pull toward technology (14:24) Studying Biotechnology (24:23) Innovation vs. novelty (32:05) Joining Recursion (40:42) What launched Enveda (49:53) Chemistry-first approach (52:17) Raising $225K and investing $55K personally (56:04) Initial studies and targets (1:18:27) Enveda’s long-term vision (1:21:31) Book recommendation
2
3
14
2,755
Viswa Colluru retweeted
This Earth Day, we're reflecting on a simple but powerful idea: 𝗻𝗮𝘁𝘂𝗿𝗲 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗿𝘂𝗻𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗼𝗻𝗴𝗲𝘀𝘁 𝗥&𝗗 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗶𝗻 𝗵𝗶𝘀𝘁𝗼𝗿𝘆. Life on Earth has built an extraordinary library of chemistry. Molecules shaped by survival, adaptation, and symbiosis. These compounds weren't designed in a lab. They were selected by nature to solve real biological challenges. At Enveda, we see this as an invitation. 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘄𝗲 𝗰𝗼𝘂𝗹𝗱 𝗹𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝘁𝗵𝗶𝘀 𝘃𝗮𝘀𝘁, 𝗹𝗮𝗿𝗴𝗲𝗹𝘆 𝘂𝗻𝗲𝘅𝗽𝗹𝗼𝗿𝗲𝗱 𝗰𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝘀𝗽𝗮𝗰𝗲? 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗲𝗻𝗰𝗼𝗱𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗮𝗿𝗼𝘂𝗻𝗱 𝘂𝘀? Protecting biodiversity isn't just about preserving ecosystems. It's about safeguarding a living, evolving source of insight into human health. This Earth Day, we're reminded that the future of medicine may depend on how well we listen to nature. #EarthDay #Biodiversity #DrugDiscovery #NatureInspired
5
7
313
Pharma spent 30 years going biology-first. Enveda is built on the opposite bet. On @generalist with @mariodgabriele: why the chemistry 4 billion years of evolution has already selected for is still the best starting material we have ...and why that question is personal for me.
For decades, drug discovery has shifted away from nature and toward biology-first approaches. @viswacolluru believes that shift was a catastrophic mistake. His company, Enveda (@enveda), has raised over $500 million to build a “search engine for nature’s chemistry.” In our conversation, we explore: • Why the pharmaceutical industry abandoned nature (and why that was a massive mistake) • How Enveda built a system to decode unknown molecules in nature • The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work • Why old ideas, from immunotherapy to natural products, often hold the most latent potential • How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million • Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis • Why first-in-class medicines capture the vast majority of returns in pharma • What competitive table tennis taught him about building companies Thank you to the partners who make this possible @brexHQ: The intelligent finance platform: brex.com/mario @ahrefs Brand Radar: Find your brand in AI results: ahrefs.com/generalist @withpersona: Trusted identity verification for any use case: withpersona.com/generalist (00:00) Introduction to Viswa Colluru (07:06) Early pull toward technology (14:24) Studying Biotechnology (24:23) Innovation vs. novelty (32:05) Joining Recursion (40:42) What launched Enveda (49:53) Chemistry-first approach (52:17) Raising $225K and investing $55K personally (56:04) Initial studies and targets (1:18:27) Enveda’s long-term vision (1:21:31) Book recommendation
1
7
28
5,225
Viswa Colluru retweeted
Innovation doesn’t stop at the bench. Clinical trials are the bottleneck, but they don’t have to be. We’re scaling a multi-asset clinical pipeline across large indications. Now we scale execution. Welcoming Chris Porter (25+ yrs scaling global clinical programs). AI/Nature-driven discovery × world-class clinical ops = faster path to new medicines Welcome, Chris 🚀 Read more: businesswire.com/news/home/2…
3
10
717
Viswa Colluru retweeted
the first public sneak peek of data from @enveda's first clinical trials this is small early data, but has the potential to be: 1) clinically differentiated and meaningfully best in class 2) small molecule vs injectable 3) active in an all-patient population, including for non responders to IL-4/IL-13/STAT6 pathway
5
3
50
12,460
Viswa Colluru retweeted
We waste too much time worrying about short term hype. Hyper-fixating on the news cycle isn’t going to fix the biggest problems facing society in the coming decades. The world needs more long term thinking. So we are launching Forecast 2050: a series of conversations with the thinkers, founders, and investors shaping the next 25 years. Thank you to @tylercowen, Scott Aaronson, @noor_siddiqui_, @soundboy, @matthewclifford, @devonzuegel, @CJHandmer, @MalcolmRifkind, Yanai Yedvab, @viswacolluru, @pablolubroth, and @PhilipJohnston for joining us. First episode with Tyler drops tomorrow. Stay tuned.
48
36
6
395
40,717